8点1氪：国航南航东航支持在“民航版12306”直销平台购票；少林寺通报新住持任职；三胎概念股集体大涨

Group 1 - The three major domestic airlines in China, Air China, China Southern Airlines, and China Eastern Airlines, have announced their support for the "Civil Aviation Version 12306" direct sales platform for ticket purchases, ensuring passenger rights [3] - The airlines have initiated direct sales of tickets through the "Hanglv Zongheng" platform, which offers transparent pricing, no bundled sales, and aligns with airline rules, ensuring information security [3] - The tickets sold on the "Hanglv Zongheng" platform are directly sourced from the airlines, unlike traditional OTAs such as Ctrip and Qunar, which rely on multiple ticket agents [3] Group 2 - The National Childcare Subsidy Implementation Plan was announced, providing an annual subsidy of 3,600 yuan for each child, regardless of whether they are the first, second, or third child, starting from January 1, 2025 [4] - Following the announcement, stocks related to the three-child policy, such as Beiyinmei and Sunshine Dairy, saw significant increases, with some stocks hitting the daily limit [4] Group 3 - The International Monetary Fund (IMF) has raised its forecast for China's economic growth this year by 0.8 percentage points to 4.8%, reflecting stronger-than-expected economic activity in the first half of the year [8] - The IMF also adjusted global economic growth forecasts for this year and next, indicating a resilient but fragile global economic outlook [8] Group 4 - Standard Chartered Group has signed a strategic cooperation memorandum with Alibaba Group to accelerate the integration of financial services and artificial intelligence technology [21] - The partnership aims to leverage Alibaba Cloud's AI capabilities to enhance financial services [21] Group 5 - Heng Rui Pharmaceutical has entered into a cooperation agreement with GlaxoSmithKline (GSK) to jointly develop up to 12 innovative drugs, with GSK paying an upfront fee of $500 million and potential milestone payments of up to $12 billion [18] - This collaboration highlights the increasing trend of multinational pharmaceutical companies partnering with domestic firms at earlier stages of drug development [18] Group 6 - The 2025 Fortune Global 500 list revealed that 130 Chinese companies made the list, with a total revenue of approximately $10.7 trillion, a decrease of about 3% compared to the previous year [11] - The average revenue of Chinese companies on the list was approximately $82 billion, lower than that of U.S. companies, which averaged $105.8 billion [11]